poisar

Stocks · News reference

Two Years to Build or Pay 200% — Which US Pharma Stocks Win?

Stjepan Kalinic

Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ABBVAMGNAMPHAMRXANIPGILDIHEPJPPPHXLVXPH
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Jake Lerch

    The Dividend Divide: Pure Dividend Strategy ETF Meets Tech-Driven Growth ETF

    iShares Core High Dividend ETF (HDV) and Fidelity High Dividend ETF (FDVV) offer contrasting approaches to dividend investing. HDV emphasizes defensive sectors like energy and staples with lower volatility and a 0.08% expense ratio, while FDVV incorporates tech exposure with higher growth potential but greater volatility and a 0.15% expense ratio. HDV has delivered 12.8% CAGR since 2021 with a 2.9% yield, while FDVV achieved 13.5% CAGR with a 2.8% yield. The choice depends on whether investors prioritize conservative income or growth-oriented dividend strategies.

    HDVFDVVCVXNVDAAAPL
  3. Delveinsight

    Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight

    Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results.

    LLYNVOVKTXRHHBYABBV
  4. Sara Appino

    AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

    AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures.

    ABBVPFEMCKCAHCOR